The point is that most customers in the Third World are not able to afford the price point that makes such medicines profitable.

The workaround since 2000-01 or so has been differential pricing or licensing for the Third World. But this took decades to get agreements for that to happen.

Here's a good page about the situation with HIV drugs. http://www.avert.org/generic.htm